VRDN - Viridian Therapeutics Inc

VRDN - Viridian Therapeutics Inc

https://www.viridiantherapeutics.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results - Viridian Therapeutics ( NASDAQ:VRDN )

Benzinga • 1 month, 1 week ago • score: 0.51

Viridian Therapeutics, Inc. VRDN reported upbeat results for the second quarter on Wednesday. The company posted quarterly losses of $ ( 1.00 ) per share which beat the analyst consensus estimate of $ ( 1.02 ) per share.

Viridian ( VRDN ) Q2 Net Loss Widens 55%

Motley Fool • 1 month, 1 week ago • score: 0.28

Viridian Therapeutics ( NASDAQ:VRDN ) , a biotechnology company focused on therapies for autoimmune diseases including thyroid eye disease ( TED ) , released its second quarter 2025 results on August 6, 2025. The report highlighted major clinical progress with its lead TED candidate, veligrotug, ...

Viridian Therapeutics, Inc. ( VRDN ) Reports Q2 Loss, Misses Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.07

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics, Inc. ( VRDN ) Reports Q1 Loss, Lags Revenue Estimates

Zacks Commentary • 4 months, 1 week ago • score: -0.03

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 8.42% and 55.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Argenx ( ARGX ) Moves 4.4% Higher: Will This Strength Last?

Zacks Commentary • 5 months ago

Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Viridian Therapeutics, Inc. ( VRDN ) Reports Q4 Loss, Lags Revenue Estimates

Zacks Commentary • 6 months, 2 weeks ago • score: 0.04

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 22.86% and 17.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Cabaletta Bio ( NASDAQ:CABA ) , C3.ai ( NYSE:AI )

Benzinga • 8 months, 3 weeks ago • score: -0.02

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc analyst Eric Heath downgraded the rating for C3.ai, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.

52W High

$27.20

52W Low

$9.90

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.58

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.18

EV/Revenue (<3 favorable)

3854.39

P/S (TTM) (<3 favorable)

5012.20

P/B (<3 favorable)

4.69

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.16%

Institutions (25–75% balanced)

118.28%

Shares Outstanding

81,662,000

Float

66,944,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

305,000

Gross Profit (TTM)

-304,273,984

EPS (TTM)

-3.57

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-1423.56%

ROE (TTM) (>15% strong)

-0.66%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.04

Momentum

Bearish momentum

Value

0.6251

Previous

0.7283

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025